Clin2Atlas
AtlasBrain & nervesNeurological disorders

Idiopathic epilepsy

3Curable in someAI-generated
Burden-over-time charts — how many people this disease affects and whether that number is rising or falling — are coming to this page. The treatability read, milestones, and live trial pipeline below are current.

Milestones

dot size = significance
199020002010202020251993 — Gabapentin approved (FDA)1993 — Felbamate approved (FDA)1994 — Lamotrigine approved (FDA)1996 — Topiramate approved (FDA)1996 — Fosphenytoin approved (FDA)1997 — Tiagabine approved (FDA)1999 — Levetiracetam approved (FDA)2000 — Zonisamide approved (FDA)2000 — Oxcarbazepine approved (FDA)2004 — Pregabalin approved (FDA)2005 — Clobazam approved (FDA)2007 — Rufinamide approved (FDA)2007 — Stiripentol approved (FDA)2008 — Lacosamide approved (FDA)2009 — Vigabatrin approved (FDA)2009 — Eslicarbazepine acetate approved (FDA)2011 — Ezogabine approved (FDA)2012 — Perampanel approved (FDA)2016 — Brivaracetam approved (FDA)2018 — Cannabidiol approved (FDA)2020 — Cenobamate approved (FDA)2022 — Ganaxolone approved (FDA)2022 — Phenobarbital approved (FDA)
1993: Drug approval — Gabapentin approved (FDA). 1993: Drug approval — Felbamate approved (FDA). 1994: Drug approval — Lamotrigine approved (FDA). 1996: Drug approval — Topiramate approved (FDA). 1996: Drug approval — Fosphenytoin approved (FDA). 1997: Drug approval — Tiagabine approved (FDA). 1999: Drug approval — Levetiracetam approved (FDA). 2000: Drug approval — Zonisamide approved (FDA). 2000: Drug approval — Oxcarbazepine approved (FDA). 2004: Drug approval — Pregabalin approved (FDA). 2005: Drug approval — Clobazam approved (FDA). 2007: Drug approval — Rufinamide approved (FDA). 2007: Drug approval — Stiripentol approved (FDA). 2008: Drug approval — Lacosamide approved (FDA). 2009: Drug approval — Vigabatrin approved (FDA). 2009: Drug approval — Eslicarbazepine acetate approved (FDA). 2011: Drug approval — Ezogabine approved (FDA). 2012: Drug approval — Perampanel approved (FDA). 2016: Drug approval — Brivaracetam approved (FDA). 2018: Drug approval — Cannabidiol approved (FDA). 2020: Drug approval — Cenobamate approved (FDA). 2022: Drug approval — Ganaxolone approved (FDA). 2022: Drug approval — Phenobarbital approved (FDA)

What's being tested now

2003: 2 trials started2006: 1 trials started2007: 1 trials started2008: 1 trials started2009: 2 trials started2010: 1 trials started2011: 4 trials started2013: 1 trials started2014: 2 trials started2015: 6 trials started2016: 6 trials started2017: 6 trials started2018: 6 trials started2019: 12 trials started2020: 14 trials started2021: 33 trials started2022: 42 trials started2023: 63 trials started2024: 105 trials started2025: 103 trials started2026: 92 trials started201020202026105

Trials started per year, stacked by phase (darker = later phase). Source: ClinicalTrials.gov via Clin2, which tracks studies recruiting in recent years — early years undercount.

See all 484 active Dravet Syndrome trials on Clin2 →

Related

Alzheimer's disease and other dementiasParkinson's diseaseMultiple sclerosisMotor neuron diseaseOther neurological disorders

Burden estimates: IHME Global Burden of Disease Study. Drug indications: ChEMBL (CC BY-SA). Trial data: ClinicalTrials.gov via Clin2. Velocity, acceleration, and turning points are computed by Clin2 — how this page is made. Treatability describes what medicine can do, not what is available everywhere. This page describes populations, not people, and is not medical advice.